Synergistic Co-Targeting of BTK and BCL2 in Mantle Cell Lymphoma

被引：1
|
作者：
Li, Yangguang [1 ]
Bouchlaka, Myriam N. [2 ,3 ]
Grindle, Kreg [1 ]
Kahl, Brad S. [4 ]
Miyamoto, Shigeki [5 ]
Yang, David T. [6 ]
Capitini, Christian M. [7 ]
Rui, Lixin [8 ,9 ]
机构：
[1] Dept Med, Madison, WI USA
[2] Univ Madison, Dept Pediat, Madison, WI USA
[3] Univ Madison, Carbone Canc Ctr, Madison, WI USA
[4] Washington Univ, St Louis, MO USA
[5] Dept Oncol, Madison, WI USA
[6] Carbone Canc Ctr, Madison, WI USA
[7] Univ Wisconsin, Dept Pediat, Madison, WI USA
[8] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[9] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
    Jing Zhang
    Xueying Lu
    Jianyong Li
    Yi Miao
    Biomarker Research, 10
  • [2] FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
    Y Li
    M N Bouchlaka
    J Wolff
    K M Grindle
    L Lu
    S Qian
    X Zhong
    N Pflum
    P Jobin
    B S Kahl
    J C Eickhoff
    S M Wuerzberger-Davis
    S Miyamoto
    C J Thomas
    D T Yang
    C M Capitini
    L Rui
    Oncogene, 2016, 35 : 6223 - 6234
  • [3] Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
    Zhang, Jing
    Lu, Xueying
    Li, Jianyong
    Miao, Yi
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [4] FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
    Li, Y.
    Bouchlaka, M. N.
    Wolff, J.
    Grindle, K. M.
    Lu, L.
    Qian, S.
    Zhong, X.
    Pflum, N.
    Jobin, P.
    Kahl, B. S.
    Eickhoff, J. C.
    Wuerzberger-Davis, S. M.
    Miyamoto, S.
    Thomas, C. J.
    Yang, D. T.
    Capitini, C. M.
    Rui, L.
    ONCOGENE, 2016, 35 (48) : 6223 - 6234
  • [5] Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
    Agarwal, Rishu
    Dawson, Mark A.
    Dreyling, Martin
    Tam, Constantine S.
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2769 - 2781
  • [6] Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
    Wang, Sicong
    Clapper, Erin
    Tonissen, Kathryn F.
    Di Trapani, Giovanna
    ANTIOXIDANTS, 2023, 12 (02)
  • [7] Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes
    Klener, Pavel, Jr.
    Trneny, Marek
    Andera, Ladislav
    Nahacka, Zuzana
    Klanova, Magdalena
    Karolova, Jana
    Svaton, Michael
    Havranek, Ondrej
    Soukup, Jan
    Zemanova, Zuzana
    Tuskova, Diana
    Pokorna, Eva
    Forsterova, Kristina
    Vockova, Petra
    Fronkova, Eva
    Prukova, Dana
    BLOOD, 2018, 132
  • [8] Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
    Axelrod, M.
    Ou, Z.
    Brett, L. K.
    Zhang, L.
    Lopez, E. R.
    Tamayo, A. T.
    Gordon, V.
    Ford, R. J.
    Williams, M. E.
    Pham, L. V.
    Weber, M. J.
    Wang, M. L.
    LEUKEMIA, 2014, 28 (02) : 407 - 410
  • [9] Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma
    M Axelrod
    Z Ou
    L K Brett
    L Zhang
    E R Lopez
    A T Tamayo
    V Gordon
    R J Ford
    M E Williams
    L V Pham
    M J Weber
    M L Wang
    Leukemia, 2014, 28 : 407 - 410
  • [10] Patient-derived organoids demonstrate synergistic effect of co-targeting Aurora kinase and prosurvival BCL2 family proteins
    Bharti, Vijaya
    Blevins, Ashlyn
    Weiss, Vivian L.
    Chen, Sheau C.
    Uzhachenko, Roman
    Richmond, Ann
    Vilgelm, Anna E.
    CANCER RESEARCH, 2020, 80 (11) : 65 - 66
12345